v3.26.1
NATURE OF BUSINESS (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Nov. 25, 2022
Apr. 20, 2022
shares
Nov. 11, 2021
$ / shares
shares
Sep. 03, 2021
USD ($)
Jul. 09, 2021
USD ($)
Dec. 07, 2020
USD ($)
Jun. 30, 2020
shares
Jan. 19, 2017
USD ($)
shares
Jul. 31, 2021
USD ($)
Dec. 31, 2025
USD ($)
Sep. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Nov. 11, 2025
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Nov. 26, 2022
USD ($)
Nov. 15, 2021
shares
Nov. 04, 2021
Apr. 06, 2021
Feb. 04, 2021
NATURE OF BUSINESS (Details) [Line Items]                                              
Stock Issued During Period, Shares, Acquisitions (in Shares) | shares             510,000,000 16,155,746,000                              
Proceeds from Sales of Business, Affiliate and Productive Assets               $ 100                              
Payments to Acquire Investments         $ 50,000                                    
Number of Units in Real Estate Property       53                                      
Number of Real Estate Properties       19                                      
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross       $ 7,626,286.37                                      
Payments to Acquire Real Estate       $ 7,000,000                                      
Real Estate, Description of Terms       (i)$1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence.                                      
Class of Warrant or Rights, Granted (in Shares) | shares     500,000                                        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares     $ 0.01                                        
Warrants and Rights Outstanding, Term     24 months                                        
Stock Issued During Period, Shares, New Issues (in Shares) | shares   500,000                                          
Investment Owned, Balance, Shares (in Shares) | shares                                       20,000,000      
Agreement, Description The Company A agrees that if the patent is sold or transferred, Men Hwei Tsai or Men Hwei, Tsai’s successor may receive a 25% gain on the transfer or sale of the interest. The Company agrees to give Men Hwei Tsai an additional 20 million AAGH shares. The Company allows Men Hwei, Tsai to use three years (from November 26, 2022 to November 25, 2025) find investors each with more than US$10 million investment. In case that no investor is found within three years, Men Hwei, Tsai agrees to return the patent to the Company, and both parties will continue to cooperate in accordance with the original contract on May 18, 2021. If Men Hwei Tsai finds an investor with an investment of at least US$10 million within three years, and the process for Men Hwei, Tsai and its investors to apply for a new drug may last for several years, then Men Hwei Tsai agrees that the Company will use the patented technology to develop dietary supplement that are helpful to Alzheimer’s disease. The Company will be responsible for marketing the dietary supplement. Men Hwei Tsai is entitled to commission equaling to 8% of sales price.                                            
Other Commitment                                     $ 34,978.48        
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest                   $ 1,112,684 $ (85,363) $ (193,702) $ (146,967) $ 1,027,321 $ (340,670)                
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation                           (82,013) (6,801)                
Equity, Including Portion Attributable to Noncontrolling Interest                   (4,715,116) $ (5,829,109) (5,576,377) $ (5,389,271) (4,715,116) (5,576,377)   $ (5,743,827) $ (5,311,599)          
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation                   $ 22,904   $ 36,040   $ 22,904 $ 36,040   $ 44,056 $ 54,943          
Corporate Joint Venture [Member]                                              
NATURE OF BUSINESS (Details) [Line Items]                                              
Payments to Acquire Interest in Joint Venture           $ 4,200,000                                  
Co-venturer [Member]                                              
NATURE OF BUSINESS (Details) [Line Items]                                              
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease)                 $ 100,000                            
Purecell Group [Member]                                              
NATURE OF BUSINESS (Details) [Line Items]                                              
Equity Method Investment, Ownership Percentage             51.00%                 51.00% 51.00%         51.00%  
JV Company [Member]                                              
NATURE OF BUSINESS (Details) [Line Items]                                              
Equity Method Investment, Ownership Percentage           60.00%                                  
Brilliant Healthcare Limited [Member]                                              
NATURE OF BUSINESS (Details) [Line Items]                                              
Equity Method Investment, Ownership Percentage           40.00%                                  
Nutrature Health LLC [Member]                                              
NATURE OF BUSINESS (Details) [Line Items]                                              
Equity Method Investment, Ownership Percentage                                         100.00%    
Gof Biotechnologies, Inc. [Member]                                              
NATURE OF BUSINESS (Details) [Line Items]                                              
Equity Method Investment, Ownership Percentage                                       100.00%      
International Institute of Great Health, Inc. (IIGH) [Member]                                              
NATURE OF BUSINESS (Details) [Line Items]                                              
Equity Method Investment, Ownership Percentage                                             100.00%
Common Stock [Member] | Co-venturer [Member]                                              
NATURE OF BUSINESS (Details) [Line Items]                                              
Payments to Acquire Interest in Joint Venture           $ 15,000,000                                  
Cash Distribution [Member] | Co-venturer [Member]                                              
NATURE OF BUSINESS (Details) [Line Items]                                              
Payments to Acquire Interest in Joint Venture           $ 3,000,000                                  
Gof Biotechnologies, Inc. [Member]                                              
NATURE OF BUSINESS (Details) [Line Items]                                              
Subsidiary, Ownership Percentage, Parent                                       75.00%      
Investment Owned, Balance, Shares (in Shares) | shares                                       60,000,000      
Subsidiary, Ownership Percentage, Noncontrolling Owner                                       25.00%